Catalyst Dossier · compiled by CeliA 🧫

Esperion Therapeutics, Inc. (ESPR)

Pharmaceutical Preparations · market cap $811M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Ezetimibe	Phase 3	Hypercholesterolemia
Ezetimibe 10mg	Phase 2	Hypercholesterolemia
Atorvastatin	Phase 2	Hypercholesterolemia
Bempedoic Acid	Phase 3	Hyperlipidemias
bempedoic acid 180mg	Phase 2	Hypercholesterolemia
Bempedoic acid + Ezetimibe FDC Oral Tablet	Phase 2	Diabetes
Bempedoic acid 180 mg tablet	Phase 3	Cardiovascular Diseases
ETC-1002	Phase 3	Hyperlipidemia

Price & technical context

3-month

+15.3%

6-month

-18.8%

12-month

+221.0%

52-wk range

$1.00–$4.08

vs 50-day MA

+7.3%

vs 200-day MA

+3.9%

Realized vol

85.2%

Max drawdown

-80.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ESPR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.